Maintain Market Perform: Balancing Potential and Uncertainty in AN2 Therapeutics' Drug Development
AN2 Therapeutics Is Maintained at In-Line by Evercore ISI Group
AN2 Therapeutics Is Maintained at In-Line by Evercore ISI Group
Evercore ISI Group Maintains In-Line on AN2 Therapeutics, Lowers Price Target to $2
Evercore ISI Group analyst Liisa Bayko maintains AN2 Therapeutics (NASDAQ:ANTX) with a In-Line and lowers the price target from $7 to $2.
Analysts Are Bullish on These Healthcare Stocks: AN2 Therapeutics, Inc. (ANTX), Heron Therapeutics (HRTX)
TD Cowen Remains a Buy on AN2 Therapeutics, Inc. (ANTX)
Oppenheimer Sticks to Their Hold Rating for AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics | 10-Q: Quarterly report
AN2 Therapeutics | 10-K/A: Annual report (Amendment)
AN2 Therapeutics 1Q Loss/Shr 56c >ANTX
AN2 Therapeutics 1Q Loss/Shr 56c >ANTX
Press Release: AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301
OPI, RVNC and AQST Are Among After Hour Movers
Maintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial Uncertainties
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOrgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increas
AN2 Therapeutics Price Target Announced at $6.00/Share by JMP Securities
AN2 Therapeutics Price Target Announced at $6.00/Share by JMP Securities
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform.
Buy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation Prospects
Oppenheimer Reiterates Perform on AN2 Therapeuticsto Perform
Oppenheimer analyst Jeff Jones reiterates AN2 Therapeutics (NASDAQ:ANTX) from Perform to Perform.
AN2 Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 — Oppenheimer Reiterates Perform → Perform 02/13/2024 109.58% Leerink Partners $23 → $7 Downgr
AN2 Therapeutics' High-Stakes Gamble: Navigating FDA Approval for Epetraborole Amid Clinical Trial Uncertainties
AN2 Therapeutics GAAP EPS of -$0.57 Beats by $0.17
No Data